RELiZORB®
(iMMOBILIZED LIPASE) CARTRIDGE

You are invited to an educational program

Addressing Fat Malabsorption in Tube Feeding with RELiZORB





PRESENTED BY

Sara Kimes MS Acute Hospital Clinical Nutrition

UPMC Shadyside

December 2, 2026

6:00PM, ET

Ruth's Chris Steak House

11500 West Huguenot Road

Midlothian, VA 23113

Please RSVP by: 11/27

Click for registration

Ashley Pinet, apinet@alcresta.com, (704) 798-6379

Topics for discussion include:

- Overview and consequences of fat malabsorption
- Current management of fat malabsorption and unmet needs
- RELiZORB benefits & clinical data
- Getting started with RELiZORB

Scan to register

INDICATION

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

- RELiZORB is for use with enteral tube feeding only; do not connect to intravenous or other medical tubing
- Medications should not be administered through RELiZORB

Review full product information for RELiZORB in the Instructions for Use at www.relizorbhcp.com.

RELiZORB, iLipase, the Alcresta capstone, and Alcresta Therapeutics are registered trademarks of Alcresta Therapeutics, Inc.
©2025 Alcresta Therapeutics, Inc. All rights reserved. REL2025-2017